ArticleBMC medicine2026
Trends and socio-economic inequalities in overweight- and obesity-related premature cardiovascular disease mortality in Australia.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New insights into inequalities in life expectancy and mortality: evidence from an Individual-level Socio-Economic Index (ISEI) in Australia.Population health metrics · 2026Article
- Prevalence and comorbidity burden of clinical obesity in US adults.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundAustralia has previously experienced adverse trends in overweight- and obesity-related cardiovascular disease (CVD) mortality. Its obesity prevalence is relatively high, increasing and shows wide socio-economic inequalities. However, socio-economic inequalities in premature overweight- and obesity-related CVD mortality rate and their trends are unknown. This study measures recent trends in premature overweight- and obesity-related CVD mortality in Australia from 2007 to 2022 and their area-level socio-economic inequalities.
methodsPremature overweight- and obesity-related CVD mortality was measured as deaths at ages 35-74 years with a CVD reported with at least one (DKOLH-CVD) or two (DKOLH2-CVD) of diabetes, chronic kidney disease, obesity, lipidemias and hypertension. Age-standardised death rates (ASDR) from Australian death registration data were calculated. Inequalities were measured using the Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) and analysed using rate ratios and the Relative Index of Inequality. Obesity prevalence data and their inequalities were also assessed using National Health Survey data.
resultsPremature overweight- and obesity-related CVD mortality, measured as the DKOLH-CVD ASDR, rose from 87.0 (95% confidence interval 84.6-89.5) per 100,000 in 2014 to 103.8 (101.1-106.5) in 2022 for males, or 19%, and from 44.6 (42.9-46.4) in 2013 to 50.5 (48.7-52.4) in 2022 for females, or 13%. When measured as DKOLH2-CVD ASDR, it increased by 37% for males and 21% for females from 2012 to 2022. DKOLH-CVD in ages 35-54 years rose by at least 45% from 2014 to 2022; average obesity prevalence since childhood or young adulthood of these age groups increased by approximately 50% from 2007 to 2022. The ratio of the male DKOLH-CVD ASDR of the most disadvantaged to the most advantaged IRSAD decile increased from 3.16 (2.93-3.41) in 2013-2015 to 3.51 (3.27-3.77) in 2020-2022 and for females from 4.55 (4.08-5.08) to 5.00 (4.51-5.54). Rate ratios were particularly high for DKOLH2-CVD and in ages 35-54 years. Similar socio-economic inequalities were found according to obesity prevalence.
conclusionsThe recent rise in premature overweight- and obesity-related CVD mortality in Australia, especially among those aged 35-54 years and in the most disadvantaged socio-economic deciles, closely mirrors Australia's increasing obesity prevalence. Failure to effectively tackle Australia's high obesity prevalence may have a significant detrimental long-term impact on mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.